Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsGold Coast Bivigam Coverage Policy | OpenPayer
    Ask Trek AI about this page
    CurrentGold Coast Health PlanPolicy N/A

    Bivigam (immune globulin) Coverage Criteria

    Customize your policy alerts

    Sign up for all goldcoasthealthplan policy alerts

    Know when goldcoasthealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and Medicare Part B coverage for Bivigam (immune globulin) administered intravenously. It applies to providers requesting coverage for eligible autoimmune, infectious, idiopathic, and other medically appropriate uses supported by the applicable Medicare LCD and medical records.

    Policy Summary
    PayerGold Coast Health Plan
    PolicyBivigam (immune globulin) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 21, 2025
    Last ReviewAug 21, 2025
    Next Review DateN/A
    Key ActionSubmit medical records documenting prior therapies and responses to treatment with each Bivigam prior authorization request.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    J1556HCPCS code
    500 mgBilling unit
    2 yearsCoverage duration
    5 gm/50 mLProduct supply

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Bivigam Coverage Criteria

    Bivigam Coverage Criteria

    Bivigam is covered when all applicable requirements below are met.

    ALL of the following

    • Requested treatment is for a covered use of Bivigam (immune globulin), an intravenous immunoglobulin (IVIG) consisting of human-derived antibodies used to treat autoimmune, infectious, and idiopathic diseases, including but not limited to Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Chronic Lymphocytic Leukemia (CLL), and multiple myeloma.
    • Medical records supporting the request are provided, including documentation of prior therapies and responses to treatment.

      Required medical information must accompany the request.

    • The requested use follows CMS Local Coverage Determination (LCD) L34771, Immune Globulin.

      See https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=34771&ver=49 for the applicable LCD.

    • The requested dose is consistent with FDA-approved labeling or accepted standards of medical practice.

      Refer to the Gold Coast Health Plan Medicare Part B Reference and Summary of Evidence document.

    • The requested quantity and billing are for HCPCS J1556, Bivigam (immune globulin) intravenous, billed in 500-mg units; Bivigam is supplied as 5 g/50 mL single-dose vials.
    • Coverage is requested within the approved coverage duration of two years.<= 2 years

      Dose approval is according to FDA-approved labeling or accepted standards of medical practice.

    Initial Therapy Requirements

    Initial Therapy Requirements

    Initial requests require supporting documentation and must comply with the applicable immune globulin LCD:

    All of the following

    • Submit medical records supporting the request, including documentation of prior therapies and responses to treatment.
    • Demonstrate that use follows LCD L34771 (Immune Globulin).

    Billing and Coding

    Covered HCPCS CodesHCPCSCovered
    J1556Bivigam (immune globulin) intravenous
    Bivigam billing information
    Billing unit500 mg
    HCPCS codeJ1556
    How supplied5 gm/50 mL single-dose vial (SDV)

    Prior Authorization and Documentation

    Prior Authorization

    Include prior therapy history with Bivigam requests

    Prior authorization requests for Bivigam must include medical records documenting prior therapies and responses to treatment. The request must also follow LCD L34771 (Immune Globulin).

    Documentation Required

    Provide required medical records

    Submit medical records supporting the request, including documentation of prior therapies and responses to treatment.

    Bivigam Background

    Bivigam is an intravenous immune globulin (IVIG) product containing human-derived antibodies. It is used for various autoimmune, infectious, and idiopathic diseases, including chronic inflammatory demyelinating polyneuropathy (CIDP), chronic lymphocytic leukemia (CLL), and multiple myeloma. Coverage is subject to the applicable Medicare immune globulin LCD and supporting medical documentation.

    Key Terms

    Bivigam
    ProductBivigam
    TypeIntravenous immunoglobulin (IVIG)
    DescriptionContains human-derived antibodies used to treat various autoimmune, infectious, and idiopathic diseases.
    CIDP
    AbbreviationCIDP
    Full nameChronic Inflammatory Demyelinating Polyneuropathy
    Policy contextListed among the covered uses for Bivigam.
    CLL
    AbbreviationCLL
    Full nameChronic Lymphocytic Leukemia
    Policy contextListed among the covered uses for Bivigam.
    Policy Summary
    PayerGold Coast Health Plan
    PolicyBivigam (immune globulin) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 21, 2025
    Last ReviewAug 21, 2025
    Next Review DateN/A
    Key ActionSubmit medical records documenting prior therapies and responses to treatment with each Bivigam prior authorization request.
    SourceLink
    On This Page
    Bivigam Coverage CriteriaInitial Therapy RequirementsBilling and CodingPrior Authorization and DocumentationBivigam BackgroundKey Terms